Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 7Oxaliplatin 6Nivolumab 5Leucovorin 5fludarabine 4Paclitaxel 4Docetaxel 4Cyclophosphamide 4Capecitabine 4zimberelimab 3pembrolizumab 3aldesleukin 3Trastuzumab 3Ramucirumab 3ulixertinib 2trastuzumab deruxtecan 2fludarabine phosphate 2Specimen Handling 2Irinotecan 2Cisplatin 2zolbetuximab 1zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1toripalimab 1tislelizumab 1sodium propionate 1sapanisertib 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Diagnostic Imaging × 30 days × Clear all
NCT03745326 2026-05-19

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
5 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡